Get the Stockscreener App
18.00
1.75%
-0.32
Pre-market:
18.08
0.08
+0.44%
Eyepoint Inc stock is traded at $18.00, with a volume of 1.72M.
It is down -1.75% in the last 24 hours and up +45.99% over the past month.
EyePoint Inc focuses on developing and commercializing innovative therapeutics for serious retinal diseases. It develops therapies for serious retinal diseases to provide durable treatments that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained release product candidate for retinal diseases with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
See More
Previous Close:
$18.32
Open:
$17.625
24h Volume:
1.72M
Relative Volume:
1.31
Market Cap:
$1.49B
Revenue:
$46.02M
Net Income/Loss:
$-70.80M
P/E Ratio:
-9.8901
EPS:
-1.82
Net Cash Flow:
$-1.61M
1W Performance:
+1.35%
1M Performance:
+45.99%
6M Performance:
+51.52%
1Y Performance:
+196.05%
1-Day Range:
$17.14
$18.45
1-Week Range:
$16.92
$18.87
52-Week Range:
$3.91
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Name
Eyepoint Inc
Sector
Industry
Phone
617-926-5000
Address
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
18.00 | 1.52B | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-22-24 | Initiated | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Nov-04-19 | Resumed | Laidlaw | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
View All
Eyepoint Inc Stock (EYPT) Latest News
EyePoint (EYPT) Q4 2025 Earnings Call Transcript - The Globe and Mail
Is It Too Late To Consider EyePoint (EYPT) After A 1‑Year Surge And DCF Upside? - simplywall.st
EyePoint: Fourth Quarter Financial Results Overview - Bitget
EyePoint Inc (EYPT) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline Amid Promising Clinical Advances - GuruFocus
Chardan raises EyePoint stock price target to $29 on cash position - Investing.com UK
EYPT (EyePoint) Equity-to-Asset : 0.80 (As of Sep. 2025) - GuruFocus
Chardan Capital Issues Positive Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price - MarketBeat
Chardan Capital Raises Price Target for EYPT to $29.00, Maintains Buy Rating | EYPT Stock News - GuruFocus
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 4.7%Should You Sell? - MarketBeat
Earnings call transcript: Eyepoint Pharmaceuticals Q4 2025 reveals revenue drop - Investing.com South Africa
EyePoint Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Eyepoint Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
EYPT: DURAVYU's pivotal Phase III trials progress with strong safety, efficacy, and funding into 2027 - TradingView
EYPT: DURAVYU advanced in pivotal trials with strong cash reserves and key data readouts ahead - TradingView
EyePoint Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eyepoint Pharma earnings missed by $0.06, revenue fell short of estimates - Investing.com Canada
EyePoint, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
EyePoint Inc (NASDAQ:EYPT) Stock Falls on Q4 Earnings and Revenue Miss - ChartMill
EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates - Nasdaq
EyePoint Pharmaceuticals' Q4 Net Loss Widens, Revenue Drops - marketscreener.com
Earnings Flash (EYPT) EyePoint Posts Q4 Net Loss $0.81 a Share, vs. FactSet Est of $0.77 Loss - marketscreener.com
Earnings Flash (EYPT) EyePoint, Inc. Reports Q4 Revenue $620,000, vs. FactSet Est of $990,000 - marketscreener.com
EYPT Forecasts Financial Stability Through Key Program Milestones - GuruFocus
EYEPOINT PHARMACEUTICALS ($EYPT) Releases Q4 2025 Earnings - Quiver Quantitative
EyePoint: Q4 Earnings Snapshot - marketscreener.com
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments - TradingView
EYPT: DURAVYU Phase 3 trials progress, with strong cash reserves funding operations into Q4 2027 - TradingView
EyePoint (Nasdaq: EYPT) deepens 2025 loss while pushing DURAVYU into Phase 3 - Stock Titan
Earnings Summary: EyePoint Q4 - Benzinga
EyePoint at TD Cowen Conference: DURAVYU’s Market Potential By Investing.com - Investing.com Canada
EYPT: Phase 3 trials advance with unique IL-6 mechanism, targeting a $15B global retina market - TradingView
A Preview Of EyePoint Pharmaceuticals's Earnings - Benzinga
EyePoint Pharmaceuticals to Announce Q4 Earnings on March 4 - Intellectia AI
Eyepoint Pharma earnings up next as pivotal trial data looms By Investing.com - Investing.com Canada
Eyepoint Pharma earnings up next as pivotal trial data looms - Investing.com Nigeria
EyePoint Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Performance Metrics - Markets Mojo
EyePoint begins dosing in phase 3 DME trials for DURAVYU - Eyes On Eyecare
EYPT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
EyePoint doses first patients in phase 3 DME trials for DURAVYU - Investing.com Australia
Eyepoint Inc topline data for Duravyu in dme anticipated in 2h 2027 - marketscreener.com
Eyepoint Inc Topline Data For Duravyu In Dme Anticipated In 2H 2027 - TradingView
EyePoint Doses First Patients in Phase 3 Trials of Duravyu in Diabetic Macular Edema - marketscreener.com
EyePoint Starts Global Phase 3 Trials for DURAVYU - TipRanks
EyePoint doses first patients in Phase 3 COMO and CAPRI trials for DURAVYU in DME - TradingView
EyePoint (EYPT) doses first patients in DURAVYU Phase 3 DME trials - Stock Titan
Six-month EyePoint eye implant in late-stage tests for diabetic vision loss - Stock Titan
Is EyePoint (EYPT) Recasting Its Ophthalmology Playbook With a Veteran Launch Executive at DURAVYU? - simplywall.st
EyePoint, Inc. (EYPT) Stock Analysis: Unpacking The 103% Potential Upside - DirectorsTalk Interviews
Paradigm Biocapital Advisors LP Increases Stake in EyePoint Inc - GuruFocus
EyePoint Pharmaceuticals Hits Day High with 11.22% Surge in Stock Price - Markets Mojo
EyePoint Pharmaceuticals Opens with 11.81% Gain, Outperforming S&P 500's 0.69% Increase - Markets Mojo
Eyepoint Inc Stock (EYPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):